Gilberto Fisone, Ph.D.

Laboratory of Molecular Neuropharmacology

Research Focus

We study the mechanisms of action of drugs that act at the level of the basal ganglia, a group of subcortical structures involved in the execution of voluntary movements, as well as in cognitive, motivational and emotional aspects of motor function. The striatum, which is the major component of the basal ganglia, is targeted by substances of abuse and by dopaminergic drugs used in the treatment of Parkinson's disease, schizophrenia and ADHD. Our goal is to identify molecular events occurring in distinct populations of striatal neurons and to assess their role in physiological and pathological responses. This is achieved by: (1) examining changes produced by drugs on specific components of the signal transduction machinery, and (2) determining the physiological significance of these changes through behavioral analyses of transgenic mice. Using this approach we have identified key molecular events underlying the actions of caffeine, cannabinoids and morphine. Currently, we are investigating the molecular basis of the severe motor complications, or dyskinesia, caused by prolonged administration of L-DOPA, the most common antiparkinsonian medication. In other studies, we are examining the effects produced by dopamine receptor agonists and antagonists, including typical and atypical antipsychotic drugs, on signal transduction processes in the basal ganglia and other brain regions.

Selected Publications

• Laboratory of Molecular Neuropharmacology website